Atea Pharmaceuticals Inc.
AVIR | NASDAQ
$5.58
+$0.15 (+2.76%)
Sep 22, 2026, 2:09 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | 351.37M | 48.63M |
Cost of Revenue | n/a | 83.37M | 70.09M | 62.39M | 167.21M | 38.02M |
Gross Profit | n/a | -83.37M | -70.09M | -62.39M | 184.16M | 10.61M |
Operating Income | -180.89M | -192.95M | -164.16M | -130.65M | 138.38M | -11.03M |
Interest Income | 16.38M | 25.49M | 29.22M | 11.15M | 213K | 83K |
Pretax Income | -164.51M | -167.46M | -134.94M | -119.5M | 138.59M | -10.95M |
Net Income | -158.35M | -168.39M | -135.96M | -115.91M | 121.19M | -10.95M |
Selling & General & Admin | 32.86M | 48.85M | 49.92M | 48.71M | 45.79M | 21.64M |
Research & Development | 148.02M | 145.4M | 132.84M | 88.84M | 167.21M | 38.02M |
Other Expenses | n/a | -84.67M | -88.69M | -69.29M | -167.21M | -38.02M |
Operating Expenses | 180.89M | 109.58M | 94.07M | 68.26M | 45.79M | 21.64M |
Interest Expense | n/a | n/a | n/a | 11.15M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 180.89M | 192.95M | 164.16M | 130.65M | 212.99M | 59.66M |
Income Tax Expense | -6.16M | 925K | 1.02M | -3.59M | 17.4M | n/a |
Shares Outstanding (Basic) | 81.5M | 84.26M | 83.39M | 83.25M | 82.82M | 82.44M |
Shares Outstanding (Diluted) | 81.5M | 84.26M | 83.39M | 83.25M | 88.25M | 82.44M |
EPS (Basic) | -1.94 | -2 | -1.63 | -1.39 | 1.46 | -0.13 |
EPS (Diluted) | -1.94 | -2 | -1.63 | -1.39 | 1.37 | -0.13 |
EBITDA | -164.1M | -131.8M | -119.59M | -110.84M | 138.62M | -11.01M |
EBIT | -164.51M | -132.22M | -120.01M | -111.1M | 138.59M | -11.03M |
Depreciation & Amortization | 416K | 416K | 416K | 260K | 29K | 19K |
Add to Watchlist
Select watchlists to add or remove AVIR